Literature DB >> 6703444

Keratoconjunctivitis sicca: histopathologic study of nictitating membrane and lacrimal glands from 28 dogs.

R L Kaswan, C L Martin, W L Chapman.   

Abstract

Forty nictitating membrane glands and 9 main lacrimal glands were obtained for histologic evaluation from 28 dogs with keratoconjunctivitis sicca as the result of azosulfapyridine toxicity, canine distemper, multisystemic autoimmune disease (Sjögren's syndrome-like syndrome), congenital origin, and unilateral and bilateral idiopathic keratoconjunctivitis sicca. Similar glands from 6 control dogs were studied. The most prevalent (87%) histopathologic finding was variable degrees of multifocal chronic adenitis, characterized by acinar atrophy and replacement with increased numbers of plasma cells and lymphocytes within increased amounts of interacinar fibrous connective tissue stroma. Occasional tubular structures were dilated and filled with neutrophils and cellular debris.

Entities:  

Mesh:

Year:  1984        PMID: 6703444

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  10 in total

1.  Comprehensive Clinical, Diagnostic, and Advanced Imaging Characterization of the Ocular Surface in Spontaneous Aqueous Deficient Dry Eye Disease in Dogs.

Authors:  Brian C Leonard; Kathleen A Stewart; Gillian C Shaw; Alyssa L Hoehn; Amelia A Stanley; Christopher J Murphy; Sara M Thomasy
Journal:  Cornea       Date:  2019-12       Impact factor: 2.651

2.  Evaluation of novel dry eye model: preganglionic parasympathetic denervation in rabbit.

Authors:  Hiroshi Toshida; Doan H Nguyen; Roger W Beuerman; Akira Murakami
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-10       Impact factor: 4.799

3.  Long-term topical cyclosporine treatment improves tear production and reduces keratoconjunctivitis in rabbits with induced autoimmune dacryoadenitis.

Authors:  Padmaja B Thomas; Deedar M Samant; Zejin Zhu; Shivaram Selvam; Douglas Stevenson; Yanru Wang; Sang W Song; Austin K Mircheff; Joel E Schechter; Samuel C Yiu; Melvin D Trousdale
Journal:  J Ocul Pharmacol Ther       Date:  2009-06       Impact factor: 2.671

4.  An investigation comparing the efficacy of topical ocular application of tacrolimus and cyclosporine in dogs.

Authors:  Diane V H Hendrix; Elizabeth A Adkins; Daniel A Ward; Jamie Stuffle; Brian Skorobohach
Journal:  Vet Med Int       Date:  2011-05-23

5.  Immunohistochemical evaluation of lymphocyte populations in the nictitans glands of normal dogs and dogs with keratoconjunctivitis sicca.

Authors:  David L Williams; And Alice Tighe
Journal:  Open Vet J       Date:  2018-01-05

6.  Computed tomographic imaging characteristics of the normal canine lacrimal glands.

Authors:  Allison L Zwingenberger; Shin A Park; Christopher J Murphy
Journal:  BMC Vet Res       Date:  2014-05-22       Impact factor: 2.741

7.  Clinical evaluation of a nutraceutical diet as an adjuvant to pharmacological treatment in dogs affected by Keratoconjunctivitis sicca.

Authors:  Simona Destefanis; Daniela Giretto; Maria Cristina Muscolo; Alessandro Di Cerbo; Gianandrea Guidetti; Sergio Canello; Angela Giovazzino; Sara Centenaro; Giuseppe Terrazzano
Journal:  BMC Vet Res       Date:  2016-09-22       Impact factor: 2.741

Review 8.  Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management.

Authors:  Pier Luigi Dodi
Journal:  Vet Med (Auckl)       Date:  2015-10-30

9.  Changes in tear protein profile in dogs with keratoconjunctivitis sicca following topical treatment using cyclosporine A.

Authors:  Metita Sussadee; Rucksak Rucksaken; Phattara-Orn Havanapan; Onrapak Reamtong; Aree Thayananuphat
Journal:  Vet World       Date:  2021-06-30

10.  Systemic Treatment of Immune-Mediated Keratoconjunctivitis Sicca with Allogeneic Stem Cells Improves the Schirmer Tear Test Score in a Canine Spontaneous Model of Disease.

Authors:  Manuel Hermida-Prieto; Javier García-Castro; Luis Mariñas-Pardo
Journal:  J Clin Med       Date:  2021-12-20       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.